# Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Canonical URL: https://biopharmsignal.com/news/PLSE/pulse-biosciences-inc-announces-planned-redemption-of-warrants
Ticker: PLSE
Company: Pulse Biosciences
Source: Pulse Biosciences
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.pulsebiosciences.com
## Summary

HAYWARD, Calif. --(BUSINESS WIRE)--Jun. 10, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about

## Article Body
HAYWARD, Calif. --(BUSINESS WIRE)--Jun. 10, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about
## Recent Company News
- 2026-06-25 13:46 EST — [Pulse Biosciences, Inc. Announces Planned Redemption of Warrants](https://biopharmsignal.com/news/PLSE/pulse-biosciences-inc-announces-planned-redemption-of-warrants) — Source: Pulse Biosciences
- 2026-06-25 13:46 EST — [Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026](https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-2026) — Source: Pulse Biosciences
- 2026-06-25 13:46 EST — [ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million](https://biopharmsignal.com/news/PLSE/atm-equity-purchases-by-pulse-biosciences-co-chairmen-total-approximately-13-3-million) — Source: Pulse Biosciences
- 2026-06-25 13:46 EST — [Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference](https://biopharmsignal.com/news/PLSE/pulse-biosciences-to-present-at-the-bofa-securities-2026-healthcare-conference) — Source: Pulse Biosciences
- 2026-06-25 13:46 EST — [Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation](https://biopharmsignal.com/news/PLSE/pulse-biosciences-announces-clinical-data-from-npulsetm-vybrancetm-system-first-in-human-clinical-durability-study-of-benign-thyroid-nodule-ablation) — Source: Pulse Biosciences
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)